MediciNova, Inc.
MNOVNASDAQHealthcare● Active
$1.30
$-0.01(-0.76%)
Market Cap$63987620
P/E Ratio—
52W High$1.96
52W Low$1.17
MediciNova, Inc. (MNOV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MNOV · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.05
Est. -$0.06 · +16.7%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS🔥 8-Quarter EPS Beat Streak
MNOV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.06 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.06 | -$0.05 | +16.7% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Feb 20, 2026 | -$0.10 | -$0.05 | +47.4% | $0.00B | $0.00B | -0.5% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.08 | -$0.06 | +25.0% | $0.00B | — | — |
| — Q3 FY2025 | Aug 14, 2025 | -$0.07 | -$0.07 | +0.0% | $0.00B | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.14 | -$0.06 | +57.1% | — | — | — |
| — Q1 FY2025 | Feb 19, 2025 | -$0.06 | -$0.06 | +0.0% | — | — | — |
| — Q4 FY2024 | Nov 13, 2024 | -$0.06 | -$0.06 | +0.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.00B
Q1 FY2026
Feb 20, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.10
EPS Surpr.
+47.4%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.07
EPS Est.
-$0.07
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.14
EPS Surpr.
+57.1%
Revenue
—
Q1 FY2025
Feb 19, 2025
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 13, 2024
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2028 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q2 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2028 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +16.7% | $1.40 | $1.38 | -1.43% |
| ▲ Q1 FY2026 | Feb 20, 2026 | +47.4% | $1.55 | $1.50 | -3.23% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +25.0% | $1.61 | $1.57 | -2.48% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +0.0% | $1.27 | $1.30 | +2.36% |
| ▲ Q2 FY2025 | May 13, 2025 | +57.1% | $1.44 | $1.46 | +1.39% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +0.0% | $1.92 | $1.97 | +2.60% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +0.0% | $2.28 | $2.00 | -12.28% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +16.7% | $1.13 | $1.15 | +1.77% |
Q2 FY2026-1.43%
Report Date
May 15, 2026
EPS Beat/Miss
+16.7%
Price Before
$1.40
Price After
$1.38
Q1 FY2026-3.23%
Report Date
Feb 20, 2026
EPS Beat/Miss
+47.4%
Price Before
$1.55
Price After
$1.50
Q4 FY2025-2.48%
Report Date
Nov 12, 2025
EPS Beat/Miss
+25.0%
Price Before
$1.61
Price After
$1.57
Q3 FY2025+2.36%
Report Date
Aug 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.27
Price After
$1.30
Q2 FY2025+1.39%
Report Date
May 13, 2025
EPS Beat/Miss
+57.1%
Price Before
$1.44
Price After
$1.46
Q1 FY2025+2.60%
Report Date
Feb 19, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.92
Price After
$1.97
Q4 FY2024-12.28%
Report Date
Nov 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$2.28
Price After
$2.00
Q3 FY2024+1.77%
Report Date
Aug 8, 2024
EPS Beat/Miss
+16.7%
Price Before
$1.13
Price After
$1.15
Avg Beat Reaction-1.41%
Beat Rate8 / 8 quarters
Largest Move-12.28% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MNOV ends December
MediciNova, Inc. (MNOV) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.06 by +16.7%. MNOV has beaten EPS estimates for 8 consecutive quarters. The next MNOV earnings date is expected around September 1, 2026.
Each quarter, investors track MNOV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MNOV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MNOV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MNOV earnings · 5 questionsMediciNova, Inc.'s next earnings report is expected around September 1, 2026. MNOV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MNOV historically reports after market close (AMC).
MNOV earnings datewhen is MNOV earningsMNOV next earnings datewhen does MNOV report earningsMNOV earnings calendar
▸ Source: FMP · MediciNova, Inc. SEC filings · US GAAP · MediciNova, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026